Out-patient psychotherapy for borderline personality disorder: Cost-effectiveness of schema-focused therapy v. transference-focused psychotherapy

British Journal of Psychiatry

Volumn 192, Issue 6, 2008, Pages 450-457

  Van Asselt, Antoinette D I ^a   Dirksen, Carmen D ^a   Arntz, Arnoud ^b   Giesen Bloo, Josephine H ^a,b   Van Dyck, Richard ^c   Spinhoven, Philip ^d   Van Tilburg, Willem ^c   Kremers, Ismay P ^d   Nadort, Marjon ^c   Severens, Johan L ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BORDERLINE STATE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; OUTPATIENT CARE; PATIENT ASSESSMENT; PSYCHOTHERAPY; QUALITY OF LIFE; TREATMENT OUTCOME;

ADULT; AMBULATORY CARE; BORDERLINE PERSONALITY DISORDER; COST-BENEFIT ANALYSIS; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; MALE; NETHERLANDS; PERSONAL CONSTRUCT THEORY; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTHERAPY; QUALITY-ADJUSTED LIFE YEARS; TRANSFERENCE (PSYCHOLOGY); TREATMENT OUTCOME;

EID: 44949106269     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.bp.106.033597     Document Type: Article

References (33)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). American Psychiatric Association, 1994.
2. Ten Have M, Lorsheyd J, Bijl R, Osterthun P. Annual Report Mental Health Care [in Dutch]. De Tijdstroom, 1995.
3. Giesen-Bloo J, van Dyck R, Spinhoven P, van Tilburg W, Dirksen C, van Asselt T, Kremers I, Nadort M, Arntz A. Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Arch Gen Psychiatry 2006; 63: 649-58.
4. Linehan MM, Armstrong HE, Suarez A, Allmon D, Heard HL. Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Arch Gen Psychiatry 1991; 48: 1060-4.
5. Van Asselt ADI, Dirksen CD, Arntz A, Severens JL. The cost of borderline personality disorder: societal cost of illness in BPD-patients. Eur Psychiatry 2007; 22: 354-61.
6. Goossens ME, Rutten-van Molken MP, Vlaeyen JW, van der Linden SM. The cost diary: a method to measure direct and indirect costs in cost-effectiveness research. J Clin Epidemiol 2000; 53: 688-95.
7. Van den Brink M, van den Hout WB, Stiggelbout AM, Putter H, van de Velde CJ, Kievit J. Self-reports of health-care utilization: diary or questionnaire? Int J Technol Assess Health Care 2005; 21: 298-304.
8. Severens JL, Mulder J, Laheij RJ, Verbeek AL. Precision and accuracy in measuring absence from work as a basis for calculating productivity costs in The Netherlands. Soc Sci Med 2000; 51: 243-9.
9. Van den Berg B, Brouwer WB, Koopmanschap MA. Economic valuation of informal care. An overview of methods and applications. Eur J Health Econ 2004; 5: 36-45.
10. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FF. Manual for Cost Research. Methods and Unit Prices for Economic Evaluations in Health Care [in Dutch]. College voor Zorgverzekeringen, 2004.
11. Dutch Health Insurance Board. Pharmacotherapeutic Compass [in Dutch]. Amstelveen, 2000.
12. Rice DP, Cooper BS. The economic value of human life. Am J Public Health Nations Health 1967; 57: 1954-66.
13. Arntz A, van den Hoorn M, Cornelis J, Verheul R, van den Bosch WM, de Bie AJ. Reliability and validity of the borderline personality disorder severity index. J Personal Disord 2003; 17: 45-59.
14. Brooks R. EuroQol: the current state of play. Health Policy 1996; 37: 53-72.
15. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35: 1095-108.
16. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997; 6: 327-40.
17. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. Chapman & Hall, 1993.
18. Van Hout BA, Al MJ, Gordon GS, Rutten FF. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 1994; 3: 309-19.
19. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ 2005; 14: 487-96.
20. Marra CA, Woolcott JC, Kopec JA, Shojania K, Offer R, Brazier JE, Esdaile JM, Anis AH. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med 2005; 60: 1571-82.
21. Gyrd-Hansen D. Willingness to pay for a QALY. Health Econ 2003; 12: 1049-60.
22. King JT, Tsevat J, Lave JR, Roberts MS. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med Decis Making 2005; 25: 667-77.
23. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146: 473-81.
24. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13: 437-52.
25. Council for Public Health and Health Care. Sensible and Sustainable Care [in Dutch]. Den Haag, 2006.
26. Hayhurst H, Palmer S, Abbott R, Johnson T, Scott J. Measuring health-related quality of life in bipolar disorder: relationship of the EuroQol (EQ-5D) to condition-specific measures. Qual Life Res 2006; 15: 1271-80.
27. Sapin C, Fantino B, Nowicki ML, Kind P. usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health Qual Life Outcomes 2004; 2: 20.
28. Van de Willige G, Wiersma D, Nienhuis FJ, Jenner JA. Changes in quality of life in chronic psychiatric patients: a comparison between EuroQol (EQ-5D) and WHOQoL. Qual Life Res 2005; 14: 441-51.
29. Prieto L, Sacristan JA, Hormaechea JA, Casado A, Badia X, Gomez JC. Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients. Curr Med Res Opin 2004; 20: 827-35.
30. Oostenbrink JB, Al MJ. The analysis of incomplete cost data due to dropout. Health Econ 2005; 14: 763-76.
31. Rubin DB, Schenker N. Multiple imputation in health-care databases: an overview and some applications. Stat Med 1992; 10: 585-98.
32. Sculpher MJ, Claxton K, Drummond M, McCabe C. Whither trial-based economic evaluation for health care decision making? Health Econ 2006; 15: 677-87.
33. Barrett B, Byford S, Knapp M. Evidence of cost-effective treatments for depression: a systematic review. J Affect Disord 2005; 84: 1-13.